Literature DB >> 10822429

Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease.

H I Hurtig1, J Q Trojanowski, J Galvin, D Ewbank, M L Schmidt, V M Lee, C M Clark, G Glosser, M B Stern, S M Gollomp, S E Arnold.   

Abstract

BACKGROUND: Dementia is a frequent complication of idiopathic parkinsonism or PD, usually occurring later in the protracted course of the illness. The primary site of neuropathologic change in PD is the substantia nigra, but the neuropathologic and molecular basis of dementia in PD is less clear. Although Alzheimer's pathology has been a frequent finding, recent advances in immunostaining of alpha-synuclein have suggested the possible importance of cortical Lewy bodies (CLBs) in the brains of demented patients with PD.
METHODS: The brains of 22 demented and 20 nondemented patients with a clinical and neuropathologic diagnosis of PD were evaluated with standard neuropathologic techniques. In addition, CLBs and dystrophic neurites were identified immunohistochemically with antibodies specific for alpha-synuclein and ubiquitin; plaques and tangles were identified by staining with thioflavine S. Associations between dementia status and pathologic markers were tested with logistic regression.
RESULTS: CLBs positive for alpha-synuclein are highly sensitive (91%) and specific (90%) neuropathologic markers of dementia in PD and slightly more sensitive than ubiquitin-positive CLBs. They are better indicators of dementia than neurofibrillary tangles, amyloid plaques, or dystrophic neurites.
CONCLUSION: CLBs detected by alpha-synuclein antibodies in patients with PD are a more sensitive and specific correlate of dementia than the presence of Alzheimer's pathology, which was present in a minority of the cases in this series.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10822429     DOI: 10.1212/wnl.54.10.1916

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  159 in total

Review 1.  Emerging therapies in the pharmacological treatment of Parkinson's disease.

Authors:  Amos D Korczyn; Miri Nussbaum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Lewy bodies and dementia.

Authors:  D Galasko
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

3.  Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases.

Authors:  Jian-Hui Zhu; Scott M Kulich; Tim D Oury; Charleen T Chu
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

4.  Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled trial.

Authors:  Karen Marder
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

5.  Sentence processing in Lewy body spectrum disorder: the role of working memory.

Authors:  Rachel G Gross; Corey T McMillan; Keerthi Chandrasekaran; Michael Dreyfuss; Sharon Ash; Brian Avants; Philip Cook; Peachie Moore; David J Libon; Andrew Siderowf; Murray Grossman
Journal:  Brain Cogn       Date:  2012-01-02       Impact factor: 2.310

6.  An update on brain imaging in parkinsonian dementia.

Authors:  Myria Petrou; Vikas Kotagal; Nicolaas I Bohnen
Journal:  Imaging Med       Date:  2012-04

7.  Neuropathologic substrates of Parkinson disease dementia.

Authors:  David J Irwin; Matthew T White; Jon B Toledo; Sharon X Xie; John L Robinson; Vivianna Van Deerlin; Virginia M-Y Lee; James B Leverenz; Thomas J Montine; John E Duda; Howard I Hurtig; John Q Trojanowski
Journal:  Ann Neurol       Date:  2012-10-04       Impact factor: 10.422

Review 8.  The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging.

Authors:  Nicola J Ray; Antonio P Strafella
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

Review 9.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

10.  Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's disease.

Authors:  K Hamada; M Hirayama; H Watanabe; R Kobayashi; H Ito; T Ieda; Y Koike; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.